Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas

Alberto Ballestrero, Davide Boy, Roberta Gonella, Maurizio Miglino, Marino Clavio, Valentina Barbero, Alessio Nencioni, Marco Gobbi, Franco Patrone

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg-1 day-1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence of grade III-IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among the patients with solid tumours (p=0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological recovery. According to the present study design and taking into account the current prices in our institution, the cost of the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day +5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalAnnals of Hematology
Volume87
Issue number1
DOIs
Publication statusPublished - Jan 2008

Keywords

  • Autologous bone marrow transplantation
  • Filgrastim
  • Lymphomas
  • Pegfilgrastim
  • Solidtumours

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas'. Together they form a unique fingerprint.

Cite this